Condition: Decompensated Liver Cirrhosis · Sponsor: Institute of Liver and Biliary Sciences, India
Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores. This study was designed to evaluate potential clinical benefit of repeated cycles of granulocyte-colony stimulating factor (G-CSF) and DARBEPOETIN versus single cycle on delta change in immunometabolic profile of patients at 6 months assessed in terms of -Change in innate immunity -Monocyte, neutrophils -distribution , function and bioenergetic adaptation .
This description comes directly from the study's public registry record.
Dr Shreya Singh, MD · 01146300000 · shreyasingh2746@gmail.com
Dr Manoj Kumar Sharma, DM · 01146300000 · manojkumardm@gmail.com
Always discuss trial participation with your own doctor first.
| Institute of Liver & Biliary Sciences (ILBS) | New Delhi, National Capital Territory of Delhi, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07002827